Related Experiment Video
Updated: May 13, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Polycythemia vera: current pharmacotherapy and future directions.
Benjamin Hensley1, Holly Geyer, Ruben Mesa
1Mayo Clinic, Department of Internal Medicine, Scottsdale, AZ, USA.
Expert Opinion on Pharmacotherapy
|March 14, 2013
Summary
Polycythemia vera (PV) management is evolving beyond phlebotomy and aspirin. New therapies like pegylated interferon and JAK inhibitors show promise in controlling vascular events and hematopoiesis.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Traditional polycythemia vera (PV) management focused on phlebotomy and low-dose aspirin.
- Cytoreductive therapies historically aimed to reduce vascular events but did not impede disease progression.
Purpose of the Study:
- To review current and emerging therapeutic strategies for polycythemia vera.
- To evaluate the efficacy of novel agents in managing hematocrit, vascular events, and disease progression.
Main Methods:
- Review of recent clinical trials and therapeutic advancements in PV management.
- Analysis of data on pegylated interferon alpha-2a and JAK inhibitors (e.g., ruxolitinib).
Main Results:
- Optimal hematocrit control (<45%) reduces vascular event risk.
- Pegylated interferon alpha-2a demonstrates potential in controlling vascular events, hematopoiesis, fibrosis, and JAK2 V1617F allele burden.
- JAK inhibitors show significant impact on vascular events, hematopoiesis, and symptomatic burden in PV.
Conclusions:
- Emerging therapies like pegylated interferon and JAK inhibitors represent a shift from historical PV management.
- Future research should explore combination therapies involving JAK inhibitors for enhanced efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...